DK0661920T3 - Anvendelse af psoralen-forbindelser til inhibering af restenose efter angioplastik - Google Patents

Anvendelse af psoralen-forbindelser til inhibering af restenose efter angioplastik

Info

Publication number
DK0661920T3
DK0661920T3 DK93901142T DK93901142T DK0661920T3 DK 0661920 T3 DK0661920 T3 DK 0661920T3 DK 93901142 T DK93901142 T DK 93901142T DK 93901142 T DK93901142 T DK 93901142T DK 0661920 T3 DK0661920 T3 DK 0661920T3
Authority
DK
Denmark
Prior art keywords
photopheresis
patient
blood
affected tissue
vivo
Prior art date
Application number
DK93901142T
Other languages
Danish (da)
English (en)
Inventor
Emil Bisaccia
Albert S Klainer
Original Assignee
Emil Bisaccia
Albert S Klainer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emil Bisaccia, Albert S Klainer filed Critical Emil Bisaccia
Application granted granted Critical
Publication of DK0661920T3 publication Critical patent/DK0661920T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Details Of Rigid Or Semi-Rigid Containers (AREA)
DK93901142T 1991-12-17 1992-12-17 Anvendelse af psoralen-forbindelser til inhibering af restenose efter angioplastik DK0661920T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/809,590 US5284869A (en) 1991-12-17 1991-12-17 Photophoresis methods for treating atherosclerosis and for preventing restenosis following angioplasty
PCT/US1992/010982 WO1993011657A2 (en) 1991-12-17 1992-12-17 The use of psoralen compounds to inhibit restenosis following angioplasty

Publications (1)

Publication Number Publication Date
DK0661920T3 true DK0661920T3 (da) 1999-10-25

Family

ID=25201702

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93901142T DK0661920T3 (da) 1991-12-17 1992-12-17 Anvendelse af psoralen-forbindelser til inhibering af restenose efter angioplastik

Country Status (9)

Country Link
US (2) US5284869A (es)
EP (1) EP0661920B1 (es)
AT (1) ATE178757T1 (es)
AU (2) AU3328393A (es)
DE (1) DE69228952T2 (es)
DK (1) DK0661920T3 (es)
ES (1) ES2131572T3 (es)
GR (1) GR3032388T3 (es)
WO (1) WO1993011657A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284869A (en) * 1991-12-17 1994-02-08 Emil Bisaccia Photophoresis methods for treating atherosclerosis and for preventing restenosis following angioplasty
US5116864A (en) * 1991-04-09 1992-05-26 Indiana University Foundation Method for preventing restenosis following reconfiguration of body vessels
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6395494B1 (en) * 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6663881B2 (en) * 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
DE69435137D1 (de) * 1993-05-13 2008-10-16 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
CA2223595C (en) 1995-06-07 2008-08-05 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US6008211A (en) * 1995-07-27 1999-12-28 Pdt Pharmaceuticals, Inc. Photoactivatable compounds comprising benzochlorin and furocoumarin
US5902299A (en) * 1997-07-29 1999-05-11 Jayaraman; Swaminathan Cryotherapy method for reducing tissue injury after balloon angioplasty or stent implantation
AU2412800A (en) * 1999-01-15 2000-08-01 Light Sciences Corporation Noninvasive vascular therapy
US6602274B1 (en) 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
ATE309807T1 (de) * 1999-09-24 2005-12-15 Vasogen Ireland Ltd Zusammensetzung zur behandlung von atherosklerose,welche ein statin und ex-vivo behandeltes blut enthält
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US7479123B2 (en) 2002-03-04 2009-01-20 Therakos, Inc. Method for collecting a desired blood component and performing a photopheresis treatment
US8109981B2 (en) * 2005-01-25 2012-02-07 Valam Corporation Optical therapies and devices
WO2007106856A2 (en) * 2006-03-14 2007-09-20 Allux Medical, Inc. Phototherapy device and method of providing phototherapy to a body surface
US20070219600A1 (en) * 2006-03-17 2007-09-20 Michael Gertner Devices and methods for targeted nasal phototherapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4321919A (en) * 1979-12-11 1982-03-30 Leukocyte Research, Inc. Method and system for externally treating human blood
US4683889A (en) * 1983-03-29 1987-08-04 Frederic A. Bourke, Jr. Method and system for externally treating the blood
US5284869A (en) * 1991-12-17 1994-02-08 Emil Bisaccia Photophoresis methods for treating atherosclerosis and for preventing restenosis following angioplasty
US5116864A (en) * 1991-04-09 1992-05-26 Indiana University Foundation Method for preventing restenosis following reconfiguration of body vessels

Also Published As

Publication number Publication date
AU3688497A (en) 1997-12-18
DE69228952T2 (de) 1999-10-21
AU3328393A (en) 1993-07-19
DE69228952D1 (de) 1999-05-20
WO1993011657A2 (en) 1993-06-24
ATE178757T1 (de) 1999-04-15
ES2131572T3 (es) 1999-08-01
EP0661920A4 (en) 1995-03-02
EP0661920B1 (en) 1999-04-14
GR3032388T3 (en) 2000-05-31
US5284869A (en) 1994-02-08
EP0661920A1 (en) 1995-07-12
US5426116A (en) 1995-06-20

Similar Documents

Publication Publication Date Title
DK0661920T3 (da) Anvendelse af psoralen-forbindelser til inhibering af restenose efter angioplastik
US5514707A (en) Inhibition of smooth muscle cell proliferation by 8-methoxypsoralen photoactivated by visible light
AU651701B2 (en) Method for preventing restenosis following reconfiguration of body vessels
Lui et al. Photodynamic therapy in dermatology: recent developments
DE69201948D1 (de) Verwendung von 1,3-oxathiolanalogen von nukleosiden zur herstellung eines arzneimittels zur behandlung von hepatitis-b.
BRPI0111591B8 (pt) composto, composição farmacêutica, e, usos de um composto
DE59606784D1 (de) Verwendung von boswelliasäure und ihren derivaten zur hemmung der normalen und gesteigerten leukozytenelastase- oder plasminaktivität
CA2295572A1 (en) Treatment of inflammatory disorders of the bowel and urinary bladder
Gasparro et al. The excitation of 8‐methoxypsoralen with visible light: reversed phase HPLC quantitation of monoadducts and cross‐links
CA2270558A1 (en) Treatment of autoimmune diseases by photochemotherapy
WO2003045311A3 (en) Methods for inhibiting or suppressing stenosis of arteriovenous access fistulas and grafts
CA2117330C (en) The use of psoralen compounds to inhibit restenosis following angioplasty
AU753208B2 (en) The use of psoralen compounds to inhibit restenosis following angioplasty
US4939167A (en) Use of 5-methoxypsoralen and other furocoumarins as jet lag suppressants
DE69530084D1 (de) Methode zur verminderung arterieller stenose
Debta et al. Photochemotherapy (PUVA): an overview
Jurkowitsch et al. Light Treatment in Medicine
EP1291026A3 (en) Therapeutic tool for treating vascular diseases
Kumar Advances in phototherapy
DE69411833D1 (de) Verwendung von Chinonen zur Herstellung eines Arzneimittels zur Vorbeugung und Behandlung von allergischer Rhinitis
MX9702985A (es) Endoprotesis temporal de flujo pasante emisora de radiacion.
NO951966L (es)
DE60112253D1 (de) Verwendung von xanthinederivaten zur herstellung eines arzneimittels zur behandlung oder verhütung von osteoporose